Movers and SHAKERS
Helius Medical Technologies (HSDT)(HSM:CA)
CMS to Scrap MCIT? Implications for Helius
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
MCIT Concerns. The Centers for Medicare and Medicaid Services (CMS) has announced it is planning to scrap the proposed Medicare Coverage of Innovative Technology (MCIT) payment rule that would have allowed four years of Medicare coverage for breakthrough device designated technologies. While an unfortunate setback, we do not believe the potential loss of MCIT to be material to the Helius story.
Not Quite Dead Yet. While CMS may be looking to scrap MCIT following a 30 day comment period, the proposal was recently included in a discussion draft for the 21st Century Cures Act which is expected to come up in next year's legislative calendar. So a form of MCIT may be revised shortly in any case ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.